The Department of Health and Human Services today announced a $226 million contract to expand the nation’s capacity to quickly produce vaccine for a flu pandemic. HHS expects the six-year agreement with Sanofi Pasteur to increase the company’s capacity to use recombinant vaccine technology, which is faster than traditional egg-based technology, to produce a pandemic vaccine in the United States to nearly 100 million doses. Sanofi is the only company with a seasonal recombinant flu vaccine licensed in the U.S. “Keeping vaccine manufacturing in the United States is essential to protect Americans from pandemic influenza and to save lives,” said BARDA Director Rick Bright. “Better, faster vaccine technologies, produced in the U.S. will improve access, protect more people and, ultimately, strengthen our nation’s health security.” In September, President Trump created an interagency task force to develop and implement a five-year plan to improve flu vaccines and produce them faster.

 

Related News Articles

Headline
This season’s flu vaccine has been about 45% effective at preventing flu-related outpatient visits, the Centers for Disease Control and Prevention reported…
Headline
The Centers for Disease Control and Prevention continues to recommend early treatment with antiviral medications for hospitalized patients and high-risk…
Chairperson's File
Even as the government ramps up efforts to improve vaccines, the flu virus remains a wily target, mutating just enough each year to endanger millions. The…
Headline
Only one in three U.S. pregnant women receive both the flu and whooping cough vaccines as recommended, according to a Vital Signs report released today by the…
Headline
President Trump yesterday created an interagency task force to develop and implement a five-year plan to improve flu vaccines and produce them faster. “Faster…
Headline
The Centers for Disease Control and Prevention yesterday recommended treating all hospitalized, severely ill and high-risk patients who have suspected or…